Outcome of Transurethral Resection of the Prostate in Patients with chronic kidney disease.

Dr Sanjay Ramachandra Pudakalkatti; Dr Venkatesh Shivakumar; Dr Jayaram Srinivas; Dr Ramaiha Keshavamurthy

Volume : VII, Issue : III, March - 2018

Outcome of Transurethral Resection of the Prostate in Patients with chronic kidney disease.

Dr Sanjay Ramachandra Pudakalkatti, Dr Venkatesh Shivakumar, Dr Jayaram Srinivas, Dr Ramaiha Keshavamurthy

Abstract :

Introduction:

Renal failure (RF) and symptomatic benign prostatic hyperplasia (BPH) are two common health problems which co–exist in 5.9–13.6% of the male population over 50 years of age. It is usually unclear in this group of patients whether BPH is the reason for renal insufficiency or not. As it is known that RF increases the risk in prostatic surgery, a tendency towards avoiding the surgery until the detection of an absolute indication may occur.

Objectives:

To compare the prevalence of preoperative co–morbid factors and complications of transurethral resection of prostate (TURP) in patients with normal and non–dialysis requiring elevated serum creatinine levels.

Methods:

The medical records of 254 consecutive patients who underwent TURP at our institution from January 2015 to December 2016 were analysed.The preoperative Na, K, creatinine levels and the early changes observed in these parameters after TURP of the patients with normal (Group1, n = 223) and elevated (Group2, n = 31) serum creatinine levels, as well as the preoperative baseline data and postoperative complications were compared.

Results:

In group 2 patients preoperative serum creatinine, urea and K levels were significantly higher . Though co–morbid diseases were significantly more common in group2 no significant difference was observed in postoperative complications between the two groups.. No progression in renal failure or de novo need for hemodialysis was observed in group2.

Conclusions:

TURP can be safely performed in BPH patients with mild serum creatinine elevations (1.5–3 mg/dl) and moderately increased prostate volumes without additional morbidity and mortality.